Search Results

More than one fourth of AIDS patients in NYC now die from non–HIV-related causes.

In late January, the CDC released guidelines on the use of antiretroviral therapy in individuals possibly exposed to HIV through sexual intercourse, injection-drug use, or . . .

The revision includes several new clinical recommendations, as well as a provocative discussion on when to start antiretrovirals in pregnant women who do not require treatment for their own health.

Raltegravir (the first integrase inhibitor) and maraviroc (the first CCR5 inhibitor) are both effective and well tolerated in highly treatment-experienced patients.

The rapid progression of infection in the now-famous New York case was most likely due to host factors rather than a highly virulent strain of HIV.

Researchers at IAS reported on the benefits of once-daily tenofovir + FTC + efavirenz as initial therapy, described a new needle-free injection system for T-20, and announced the impending availability of lopinavir/ritonavir in tablet formulation.

Once a year may be enough in stable patients, according to the DHHS.

The latest guidelines include updated information on resistance to both old and new drugs and provide specific recommendations for the clinical application of resistance testing.

ART success rates have improved over time — currently, more than 90% of patients achieve viral suppression at 1 year — but switching because of intolerance remains common.

A retrospective review suggests that many of the most common regimens perform indistinguishably.

Treatment-naive patients receiving generic NNRTI-based potent combination antiretroviral therapy in Haiti have had positive results similar to those seen in the U.S.

CROI 2012 featured 96-week data on dolutegravir and dose-ranging data for the tenofovir prodrug GS-7340.

Both guidelines recommend earlier initiation of antiretroviral therapy for HIV-infected children and provide new guidance on which drugs to use.

The panel reaffirms its clinical recommendations, using a new rating system.

The guidelines include new background information but no new clinical recommendations.

The guidelines include new tables detailing appropriate dosing in HIV-infected pregnant women and in infants.

The guidelines have been reorganized to better reflect issues in clinical practice.

Long-term treatment with PI- but not NNRTI-based therapy slightly, but significantly, increased the risk for myocardial infarction.

In studies reported at the 2010 Retrovirus Conference, vicriviroc did not significantly improve an already-strong optimized background regimen, and a new CCR5 antagonist, TBR-652, was shown to have potent antiviral activity and several other favorable characteristics.

Data presented at IAS 2009 highlighted new approaches to PI therapy for patients with virologic suppression, including simplifying ritonavir-boosted atazanavir to unboosted atazanavir and trying to sustain suppression using darunavir without nucleosides. Success rates differed among these strategies.